GlaxoSmithKline’s Cancer Therapy Cuts Risk Of Disease Progression Or Death By 38%

GlaxoSmithKline plc said on Monday its maintenance therapy for a form of ovarian cancer reduced the risk of disease progression or death by 38% in a late-stage study in cancer patients.

The study tested the therapy, niraparib, in patients with first-line platinum responsive advanced ovarian cancer and was compared to placebo.

Niraparib is also being tested to treat other forms of ovarian and breast cancer, GlaxoSmithKline said. – Reuters